KRAS and BRAF mutations in Serbian patients with colorectal cancer

Journal of B.U.ON.

Volumn 17, Issue 3, 2012, Pages 575-580

  Jakovljevic, K ^a   Malisic, E ^a   Cavic, M ^a   Krivokuca, A ^a   Dobricic, J ^a   Jankovic, Radmila ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

BRAF; Colorectal cancer; KRAS; Mutation

Indexed keywords

B RAF KINASE;

ADULT; AGED; ARTICLE; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE MUTATION; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE K RAS; PATIENT SELECTION; SERBIA; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SERBIA;

EID: 84867497799     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Di Fiore F, Sesboue R, Michel P, Sabourin JC, Frebourg T. Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer. Br J Cancer 2010; 103:1765-1772.
2. Amado RG, WoIf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-1634.
3. Di Nicolantonio F, Martini M, Molinari F et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26:5705-5712.
4. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with Cetuximab. J Clin Oncol 2008; 26:374-379. (Pubitemid 351171687)
5. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90:675-684. (Pubitemid 28222141)
6. Kotoula V, Charalambous E, Biesmans B et al. Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics. PLoS ONE 2009; 4:e7746.
7. Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Practice 2009; 205:858-862.
8. De Roock W, Jonker DJ, Di Nicolantonio F et al. Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA 2010; 304:1812-1820.
9. Licar A, Cerkovnik P, Novakovic S. Distribution of some activating KRAS and BRAF mutations in Slovene patients with colorectal cancer. Med Oncol 2011; 28:1048-1053.
10. Santini D, Loupakis F, Vincenzi B et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 2008; 13:1270-1275.
11. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al. Oncogenic Activation of the RAS/RAF Signaling Pathway Impairs the Response of Metastatic Colorectal Cancers to Anti-Epidermal Growth Factor Receptor Antibody Therapies. Cancer Res 2007; 67:2643-2648. (Pubitemid 46548951)
12. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308. (Pubitemid 46480970)
13. Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O. Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta 2005; 1756:103-114.
14. Linardou H, Dahabreh IJ, Kanaloupiti D et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-taigeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008; 9:962-972.
15. Phillips B, Kalady M, Kim R. BRAF Testing in Advanced Colorectal Cancer: Is It Ready for Prime Time? Clin Adv Hematol Oncol 2010; 8:437-444.
16. Kalady MF, Sanchez JA, Manilich E, Hammel J, Casey G, Church JM. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum 2009; 52:1039-1045.
17. Herreros-Villanueva M, Rodrigo M, Claver M et al. KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer. Mol Biol Rep 2011; 38:1315-1320.
18. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-286. (Pubitemid 40590264)
19. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010; 28:466-474.
20. Sanchez JA, Krumroy L, Plummer S et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg 2009; 96:1196-1204.
21. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAFZRAS oncogenes and mismatch-repair status. Nature 2002; 418:934. (Pubitemid 34976022)
22. Van Krieken JHJM, Jung A, Kirchner T et al. KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 2008; 453:417-431.
23. Andreyev HJN, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85:692-696.
24. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19:508-515. (Pubitemid 351325672)
25. Brose MS, Volpe P, Feldman M et al. BRAF and RAS Mutations in Human Lung Cancer and Melanoma. Cancer Research 2002; 62:6997-7000. (Pubitemid 35424092)
26. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954. (Pubitemid 34716871)
27. Velho S, Moutinho C, Cirnes L et al. BRAF, KRAS and PIK-3CA mutations in colorectal serrated polyps and cancer: Primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 2008; 8:255.
28. Pichler M, Balic M, Stadelmeyer E et al. Evaluation of High Resolution Melting Analysis as a Diagnostic Tool to Detect the BRAF V600E Mutation in Colorectal Tumors. J Mol Diagn 2009; 11:140-147.
29. Bardelli A, Sienna S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010; 28:1254-1261.